Subtype
Nasopharyngeal Neoplasm
CI-CAN-00003401Explore in graph →
Non-malignant267 active trials1 approved drugs
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003401Explore in graph →
Clinical trials
825 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07340515 | Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial | recruiting | Phase 3 | 300 | Man HuOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT03267498 | Nivolumab + Chemoradiation in Stage II-IVB Nasopharyngeal Carcinoma (NPC) | completed | Phase 2 | 40 | Sue YomOTHER | 2 | Jan 12, 2026 | clinicaltrials |
| NCT07328841 |
| recruiting |
| Phase 3 |
| 456 |
| Ming-Yuan ChenOTHER |
| 1 |
| Jan 9, 2026 |
| clinicaltrials |
| NCT07328854 | 40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma | recruiting | Phase 3 | 346 | Ming-Yuan ChenOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT07331428 | MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC | not yet recruiting | Phase 2 | 25 | Fujian Cancer HospitalOTHER_GOV | 0 | Jan 9, 2026 | clinicaltrials |
| NCT07326358 | AI System for Anatomic Recognition & Lesion Detection in Nasopharyngolaryngoscopy: A Prospective Study | recruiting | — | 500 | Ruijin HospitalOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT05544929 | A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers | active not recruiting | Phase 1 | 126 | Novartis PharmaceuticalsINDUSTRY | 12 | Jan 6, 2026 | clinicaltrials |
| NCT04227509 | Consolidation Pembrolizumab After Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma | completed | Phase 2 | 53 | Seoul National University HospitalOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT05912582 | Prospective Study for Molecular Biomarkers and Spatial Transcriptomics of Nasopharyngeal Carcinoma | not yet recruiting | — | 60 | Jiangsu Cancer Institute & HospitalOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT03734809 | NEO-SPACE Trial: Pembrolizumab and Chemoradiation in Nasopharyngeal Cancer | active not recruiting | Phase 2 | 43 | Chinese University of Hong KongOTHER | 2 | Dec 24, 2025 | clinicaltrials |
| NCT07303023 | Individualized Neck Cervical Irradiation Prophylaxis Trial of NPC(INCIPT-NPC) | recruiting | Phase 3 | 462 | Fudan UniversityOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT04004871 | Induction Chemotherapy With Nab-paclitaxel, Cisplatin and Fluorouracil for Locoregionally Advanced Nasopharyngeal Carcinoma | completed | Phase 2 | 60 | Guangxi Medical UniversityOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT05340270 | PD-1 Inhibitor Plus GP as Neoadjuvant Therapy for Locoregionally Advanced Nasopharyngeal Carcinoma(NeoTurbo) | active not recruiting | Phase 2 | 150 | Guangxi Medical UniversityOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT07277764 | Induction High-Low Dose Radiotherapy Plus Anti-PD-1 Followed by Definitive Radiotherapy in Recurrent Nasopharyngeal Carcinoma (Single-Arm Phase II)(REDEFINE) | recruiting | Phase 2 | 23 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT07188584 | Phase III Non-Inferiority Trial: Reduced-Target vs. Full-Target IMRT After Chemo in Immunotherapy-Treated Metastatic Nasopharyngeal Cancer | recruiting | Phase 3 | 166 | Ming-Yuan ChenOTHER | 1 | Dec 9, 2025 | clinicaltrials |
| NCT07268690 | Risk-Adapted Omission of Level Va Irradiation in Nasopharyngeal Carcinoma | not yet recruiting | Phase 3 | 474 | Fujian Cancer HospitalOTHER_GOV | 1 | Dec 8, 2025 | clinicaltrials |
| NCT07267338 | Pembrolizumab + MRGOO3 as Neoadjuvant in NPC | not yet recruiting | Phase 2 | 35 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT07258979 | A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma. | recruiting | Phase 1 / Phase 2 | 202 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07252375 | A Clinical Study of Hetrombopag for Prevention of Thrombocytopenia Induced by Gemcitabine Plus Cisplatin in the Treatment of Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 35 | Fujian Cancer HospitalOTHER_GOV | 0 | Nov 26, 2025 | clinicaltrials |
| NCT07154069 | Adaptive Immunotherapy for Nasopharyngeal Carcinoma | recruiting | Phase 3 | 802 | Sun Yat-sen UniversityOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT07248670 | Concurrent Chemoradiotherapy With or Without Metronomic Capecitabine in High-Risk T1-2N1M0 NPC | active not recruiting | Phase 3 | 252 | Chongqing University Cancer HospitalOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT07248696 | Tislelizumab Plus Chemotherapy With Response-Adapted Radiotherapy for de Novo Metastatic Nasopharyngeal Carcinoma: A Prospective, Phase II Trial | active not recruiting | N/A | 32 | Chongqing University Cancer HospitalOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT06839066 | A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy | recruiting | Phase 2 | 70 | Shanghai Henlius BiotechINDUSTRY | 1 | Nov 24, 2025 | clinicaltrials |
| NCT07232680 | Prospective Immuno-Radiomic Profiling in Nasopharyngeal Carcinoma Treated With Proton or Photon Chemoradiotherapy(IMPRINT) | recruiting | — | 500 | Cheng-En HsiehOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT07238569 | Phase III Trial of EBV-DNA-Guided Adaptive Immunotherapy for Advanced Nasopharyngeal Carcinoma | not yet recruiting | Phase 3 | 516 | Sun Yat-sen UniversityOTHER | 0 | Nov 20, 2025 | clinicaltrials |
| NCT07088861 | Validation of the 9th AJCC Staging System for NPC in Non-High-Incidence Areas in China | active not recruiting | — | 1,401 | Lirong WuOTHER | 0 | Nov 18, 2025 | clinicaltrials |
| NCT03144661 | An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies | terminated | Phase 1 | 25 | Incyte CorporationINDUSTRY | 2 | Oct 21, 2025 | clinicaltrials |
| NCT04272034 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors | terminated | Phase 1 | 105 | Incyte CorporationINDUSTRY | 7 | Oct 16, 2025 | clinicaltrials |
| NCT04215978 | Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors | completed | Phase 1 | 204 | BeiGeneINDUSTRY | 8 | Oct 3, 2025 | clinicaltrials |
| NCT04458909 | Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer | terminated | Phase 3 | 15 | National Cancer Institute (NCI)NIH | 4 | Oct 3, 2025 | clinicaltrials |
| NCT06982300 | SSTR2 Imaging With [68Ga]Ga-DOTA-TOC PET/CT in NPC(NACASOR) | recruiting | Phase 1 / Phase 2 | 10 | University Medical Center GroningenOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT07198802 | Molecular Research on Predictive Efficacy and New Therapeutic Targets for Nasopharyngeal Carcinoma | not yet recruiting | — | 600 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Sep 30, 2025 | clinicaltrials |
| NCT05956587 | A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors | recruiting | Phase 2 | 121 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT05305131 | Randomised Trial of Induction Gemcitabine and Cisplatin Versus Gemcitabine, Cisplatin, Pembrolizumab and Bevacizumab (GPPB) in Nasopharyngeal Cancer | recruiting | Phase 2 | 50 | National University Hospital, SingaporeOTHER | 1 | Sep 23, 2025 | clinicaltrials |
| NCT06509009 | Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma | recruiting | Phase 2 | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT07070479 | Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial | recruiting | Phase 2 | 208 | Ming-Yuan ChenOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT06241612 | Individualized Elective Neck Irradiation in NPC Patients | recruiting | Phase 3 | 470 | Sun Yat-sen UniversityOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT04384627 | Reducing Target Volumes in NPC Treated With Induction Chemotherapy Followed by Concurrent Chemoradiotherapy(NPC-GTV) | active not recruiting | Phase 3 | 445 | Sun Yat-sen UniversityOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT07129772 | Perioperative Chemotherapy and Immunotherapy for Locally Recurrent Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 53 | The University of Hong KongOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT07138989 | EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 10 | Sun Yat-sen UniversityOTHER | 1 | Aug 24, 2025 | clinicaltrials |
| NCT07139054 | 68Ga-FAPI-46 PET/CT for the Prediction of Clinical Response to Neoadjuvant Therapy in Nasopharyngeal Carcinoma Patients | completed | — | 31 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Aug 24, 2025 | clinicaltrials |
| NCT07135804 | Iparomlimab and Tuvonralimab Injection for Untreated Locally Advanced Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 45 | Second Affiliated Hospital of Nanchang UniversityOTHER | 0 | Aug 22, 2025 | clinicaltrials |
| NCT07136519 | Toripalimab, Induction Chemotherapy, Radiation Therapy With Omega-3 for Locally Advanced Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 30 | Affiliated Hospital of Guangdong Medical UniversityOTHER | 0 | Aug 22, 2025 | clinicaltrials |
| NCT02363400 | A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA | terminated | Phase 3 | 10 | National Health Research Institutes, TaiwanOTHER | 1 | Aug 19, 2025 | clinicaltrials |
| NCT01744587 | Epstein-Barr Virus Reactivation and the Effect of EGCG on Virus Reactivation in Remission Patients(NPC) | completed | N/A | 353 | National Health Research Institutes, TaiwanOTHER | 1 | Aug 15, 2025 | clinicaltrials |
| NCT05884983 | Screening Effect of Dual-energy CT Combined With Nasopharyngeal Endoscopy for Screening Nasopharyngeal Carcinoma | recruiting | — | 12,000 | Zhongshan People's Hospital, Guangdong, ChinaOTHER | 1 | Aug 15, 2025 | clinicaltrials |
| NCT06177301 | Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC | recruiting | Phase 3 | 266 | Fudan UniversityOTHER | 1 | Aug 14, 2025 | clinicaltrials |
| NCT02795195 | Trail Evaluating Carbon Ion Radiotherapy (3 GyE Per Fraction) for Locally Recurrent Nasopharyngeal Carcinoma | completed | Phase 1 / Phase 2 | 51 | Shanghai Proton and Heavy Ion CenterOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT06688175 | IMRT Combined With Lobaplatin-based CCRT in Nasopharyngeal Carcinoma | enrolling by invitation | Phase 2 | 32 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT07110558 | Radiotherapy Omitting Prophylactic Neck Irradiation With Neoadjuvant and Adjuvant Toripalimab in Nasopharyngeal Carcinoma(PUPA) | not yet recruiting | Phase 2 | 59 | Sun Yat-sen UniversityOTHER | 1 | Aug 7, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jan 14, 2026source: clinicaltrials